# Efficacy of Adding Interleukin-2 to an Optimized Antiretroviral Regimen in HIV Patients in Therapeutic Failure (ANRS123)

> **NCT00113282** · PHASE2 · COMPLETED · sponsor: **French National Agency for Research on AIDS and Viral Hepatitis** · enrollment: 57 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Interleukin-2 (IL-2)

## Key facts

- **NCT ID:** NCT00113282
- **Lead sponsor:** French National Agency for Research on AIDS and Viral Hepatitis
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2007-12
- **Final completion:** 2008-02
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00113282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00113282, "Efficacy of Adding Interleukin-2 to an Optimized Antiretroviral Regimen in HIV Patients in Therapeutic Failure (ANRS123)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00113282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*